top of page

Press Releases 

Heligenics Unveils A First-Of-Its-Kind Precision Prescription Test For Breast Cancer Therapeutics

June 13, 2023

​

Using our proprietary GigaAssay technology we can rapidly determine which of the 10,000s of mutants would make a breast cancer patient susceptible to a drug they would want to take. Heligenics also identifies which of these variants produced resistance to the drug. 

 

Heligenics & The Jackson Laboratory Announce New Collaboration on ERBB2 Breast Cancer Gene  

May 11, 2021

​

Heligenics, Inc. today announced a new collaboration with The Jackson Laboratory (JAX). This joint project will make available the functional output of Variants of Unknown Significance (VUS) throughout key portion of the ERBB2 gene through the JAX Clinical Knowledgebase (CKB), a digital resource that connects clinicians and researchers around the globe in order to interpret complex cancer genomic profiles. 

​

The International Innovation Center @ Vegas announces new tenant: Heligenics Inc.

August 5, 2020

​

The city of Las Vegas approved today a lease with Heligenics for 1,300 square feet at IIC@Vegas’ satellite location at 833 Las Vegas Blvd. North (former Library). The IIC@Vegas at 300 S. 4th Street, which opened in September 2019, is fully occupied with ten tenants, prompting the city to expand its capacity via the satellite location.

​

Publications

Synonymous Variants of Uncertain Silence

Giacoletto CJ, Rotter JI, Grody WW, Schiller MR. Int. J. Mol. Sci. 2023, 24(13), 10556; https://doi.org/10.3390/ijms241310556 

 

The history and conceptual framework of assays and screens.

Giacoletto CJ, Schiller MR.Bioessays. 2023 Apr;45(4):e2200191. doi: 10.1002/bies.202200191. Epub 2023 Feb 15.PMID: 36789580

 

Accurate Prediction of Transcriptional Activity of Single Missense Variants in HIV Tat with Deep Learning.

Derbel H, Giacoletto CJ, Benjamin R, Chen G, Schiller MR, Liu Q.Int J Mol Sci. 2023 Mar 24;24(7):6138. doi: 10.3390/ijms24076138.PMID: 37047108 

​

Most synonymous allelic variants in HIV tat are not silent.

Giacoletto CJ, Benjamin R, Deng HW, Rotter JI, Schiller MR.Genomics. 2023 Mar 7;115(3):110603. doi: 10.1016/j.ygeno.2023.110603. Online ahead of print.PMID: 36893872 

​

Heligenics: fulfilling the promise of the functional genome to enable precision medicine

Schiller, MR. 2023 Mar 20

Biopharma Deal Issue of Nature. Invited Advertisement

​

Data supporting a saturation mutagenesis assay for Tat-driven transcription with the GigaAssay
Benjamin R, Giacoletto CJ, FitzHugh ZT, Eames D, Buczek L, Wu X, Newsome J, Han MV, Pearson T, Wei Z, Banerjee A, Brown L, Valente LJ, Shen S, Deng HW, Schiller MR. Data in Brief 28 September 2022. doi: 10.1016/j.dib.2022.108641

​

GigaAssay – An adaptable high-throughput saturation mutagenesis assay platform Genomics

Benjamin R, Giacoletto CJ, FitzHugh ZT, Eames D, Buczek L, Wu X, Newsome J, Han MV, Pearson T, Wei Z, Banerjee A, Brown L, Valente LJ, Shen S, Deng HW, Schiller MR. 26 July 2022. doi: 10.1016/j.ygeno.2022.110439

​​

GigaAssay – a high-throughput assay system for molecular functions and cell processes

Schiller MR, Benjamin R, Giacoletto CJ, FitzHugh ZT, Eames D, Buczek L, Wu X, Newsome J, Han MV, Pearson T, Wei Z, Banjeree A, Shen S, Deng HW. Jul 12, 2021. doi: 10.21203/rs.3.rs-708936/v1

​

​

bottom of page